Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* male or female infants and children ≤12 years of age~* body weight of ≥5 kg and \<35 kg,~* with a confirmed diagnosis of uncomplicated malaria caused by the P. falciparum parasite~Exclusion Criteria:~* complicated malaria~* persistent vomiting~* malaria due to parasites other than P. falciparum~* antimalarial treatment received in the past 2 weeks~* known chronic disease e.g. positive HIV status, severe cardiac, renal, or hepatic disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).